GENE THERAPY METHODS FOR ARRHYTHMOGENIC CARDIOMYOPATHY

The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGFbR2) and a second nucle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	OLIVER, Dan, DAVIDSOHN, Noah
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	OLIVER, Dan DAVIDSOHN, Noah
description	The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGFbR2) and a second nucleic acid encoding fibroblast growth factor 21 (FGF21). La présente invention concerne des méthodes de traitement d'une cardiomyopathie arythmogène (ACM) chez un sujet. Les procédés comprennent généralement l'administration au sujet d'une thérapie génique comprenant un premier acide nucléique codant pour le récepteur 2 du facteur de croissance transformant bêta soluble (sTGFbR2) et un second acide nucléique codant pour le facteur de croissance des fibroblastes 21 (FGF21).
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024064796A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024064796A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024064796A23</originalsourceid><addsrcrecordid>eNrjZDBzd_VzVQjxcA1yDIhU8HUN8fB3CVZw8w9ScAwK8ogM8fD1B6rwdFZwdgxy8fT3jfQPcAzxiORhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRiYGZibmlmaORsbEqQIA2eIpRw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>GENE THERAPY METHODS FOR ARRHYTHMOGENIC CARDIOMYOPATHY</title><source>esp@cenet</source><creator>OLIVER, Dan ; DAVIDSOHN, Noah</creator><creatorcontrib>OLIVER, Dan ; DAVIDSOHN, Noah</creatorcontrib><description>The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGFbR2) and a second nucleic acid encoding fibroblast growth factor 21 (FGF21). La présente invention concerne des méthodes de traitement d'une cardiomyopathie arythmogène (ACM) chez un sujet. Les procédés comprennent généralement l'administration au sujet d'une thérapie génique comprenant un premier acide nucléique codant pour le récepteur 2 du facteur de croissance transformant bêta soluble (sTGFbR2) et un second acide nucléique codant pour le facteur de croissance des fibroblastes 21 (FGF21).</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240328&DB=EPODOC&CC=WO&NR=2024064796A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240328&DB=EPODOC&CC=WO&NR=2024064796A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>OLIVER, Dan</creatorcontrib><creatorcontrib>DAVIDSOHN, Noah</creatorcontrib><title>GENE THERAPY METHODS FOR ARRHYTHMOGENIC CARDIOMYOPATHY</title><description>The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGFbR2) and a second nucleic acid encoding fibroblast growth factor 21 (FGF21). La présente invention concerne des méthodes de traitement d'une cardiomyopathie arythmogène (ACM) chez un sujet. Les procédés comprennent généralement l'administration au sujet d'une thérapie génique comprenant un premier acide nucléique codant pour le récepteur 2 du facteur de croissance transformant bêta soluble (sTGFbR2) et un second acide nucléique codant pour le facteur de croissance des fibroblastes 21 (FGF21).</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDBzd_VzVQjxcA1yDIhU8HUN8fB3CVZw8w9ScAwK8ogM8fD1B6rwdFZwdgxy8fT3jfQPcAzxiORhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRiYGZibmlmaORsbEqQIA2eIpRw</recordid><startdate>20240328</startdate><enddate>20240328</enddate><creator>OLIVER, Dan</creator><creator>DAVIDSOHN, Noah</creator><scope>EVB</scope></search><sort><creationdate>20240328</creationdate><title>GENE THERAPY METHODS FOR ARRHYTHMOGENIC CARDIOMYOPATHY</title><author>OLIVER, Dan ; DAVIDSOHN, Noah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024064796A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>OLIVER, Dan</creatorcontrib><creatorcontrib>DAVIDSOHN, Noah</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>OLIVER, Dan</au><au>DAVIDSOHN, Noah</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>GENE THERAPY METHODS FOR ARRHYTHMOGENIC CARDIOMYOPATHY</title><date>2024-03-28</date><risdate>2024</risdate><abstract>The present disclosure provides methods of treating an arrhythmogenic cardiomyopathy (ACM) in a subject. The methods generally comprise administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGFbR2) and a second nucleic acid encoding fibroblast growth factor 21 (FGF21). La présente invention concerne des méthodes de traitement d'une cardiomyopathie arythmogène (ACM) chez un sujet. Les procédés comprennent généralement l'administration au sujet d'une thérapie génique comprenant un premier acide nucléique codant pour le récepteur 2 du facteur de croissance transformant bêta soluble (sTGFbR2) et un second acide nucléique codant pour le facteur de croissance des fibroblastes 21 (FGF21).</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; fre
recordid	cdi_epo_espacenet_WO2024064796A2
source	esp@cenet
subjects	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
title	GENE THERAPY METHODS FOR ARRHYTHMOGENIC CARDIOMYOPATHY
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T19%3A52%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=OLIVER,%20Dan&rft.date=2024-03-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024064796A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true